Intravenous allogeneic multilineage‐differentiating stress‐enduring cells in adults with dystrophic epidermolysis bullosa: a phase 1/2 open‐label study

This publication has 10 references indexed in Scilit:

• Intravenous Injection of Muse Cells as a Potential Therapeutic Approach for Epidermolysis Bullosa
  Journal of Investigative Dermatology, 2021
• Beneficial Effect of Systemic Allogeneic Adipose Derived Mesenchymal Cells on the Clinical, Inflammatory and Immunologic Status of a Patient With Recessive Dystrophic Epidermolysis Bullosa: A Case Report
  Frontiers in Medicine, 2020
• Phase I/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa
  Journal of the American Academy of Dermatology, 2020
• Safety and Efficacy of Human Muse Cell-Based Product for Acute Myocardial Infarction in a First-in-Human Trial
  Circulation Journal, 2020
• Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility
  British Journal of Dermatology, 2020
• Cultured Epidermal Autografts from Clinically Revertant Skin as a Potential Wound Treatment for Recessive Dystrophic Epidermolysis Bullosa
  Journal of Investigative Dermatology, 2019
• Treatment of dystrophic epidermolysis bullosa with bone marrow non-hematopoeitic stem cells: a randomized controlled trial
  Dermatologic Therapy, 2015
• Potential of Systemic Allogeneic Mesenchymal Stromal Cell Therapy for Children with Recessive Dystrophic Epidermolysis Bullosa
  Journal of Investigative Dermatology, 2015
• Unique multipotent cells in adult human mesenchymal cell populations
  Proceedings of the National Academy of Sciences, 2010
• Replenishment of type VII collagen and re-epithelialization of chronically ulcerated skin after intradermal administration of allogeneic mesenchymal stromal cells in two patients with recessive dystrophic epidermolysis bullosa
  Cytotherapy, 2010